Wednesday, February 16, 2022
12:22 PM EST – Nova Mentis Life Science Corp : Announced that Nova Mentis successfully completed an oral microdose psilocybin preclinical study, in the laboratory of Dr. Viviana Trezza, Rome Tre University, Rome, Italy. The results exceeded all expectations with the findings that a very low dose of the Company’s proprietary psilocybin significantly modulated behavioural and cognitive defects, such as recognition memory, in a genetic model of fragile X syndrome. Nova Mentis Life Science Corp (C.NOVA) shares were up 0.02 cents at 0.07.
Stocks in Play: Nova Mentis Life Science Corp, Wed, 16 Feb 2022 12:27:06 EST